Biologic Medicines in Australia

At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.

Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.

We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.

 

How Is The Market Landscape Evolving In Australia?

Biologic medicines represent a significant portion of the national healthcare budget and cost the PBS approximately $2.84 billion in 2017*1. It is an area where significant cost savings could be realised, with savings from biosimilars over the next five years estimated at $880 million2. These savings can be used to subsidise new biologic therapies, new indications of current biologic therapies, or other medicines and services, increasing patient access to treatments throughout the healthcare system.

The next decade will see a number of biologic medicines, across multiple therapeutic areas, coming off patent and many new originator biologic and biosimilar medicines registered. The biologics market is a constantly evolving area that is at the forefront of modern medical research.

Some key biologic medicines are listed below, categorised into their therapeutic areas.

*All products contributing to this IMS sales figure are listed on the PBS for reimbursement, however not all sales may have been PBS reimbursable sales.